- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05770531
Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy
A Randomized Clinical Trial Comparing ctDNA-Directed Therapy Change With Standard of Care in Patients With Metastatic Triple Negative Breast Cancer
Study Overview
Status
Detailed Description
Primary Objective:
- To determine whether patients with metastatic TNBC who undergo treatment changes guided by ctDNA dynamics demonstrate improved progression-free survival (PFS) compared to control patients assessed conventionally with imaging alone.
PRIMARY OBJECTIVE:
I. To determine whether patients with metastatic TNBC who undergo treatment changes guided by ctDNA dynamics demonstrate improved progression-free survival (PFS) compared to control patients assessed conventionally with imaging alone.
SECONDARY OBJECTIVES:
- To evaluate the overall response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria in patients with metastatic TNBC who undergo treatment changes guided by ctDNA dynamics compared to control patients assessed by conventional imaging alone.
- To determine whether patients with metastatic TNBC who undergo treatment changes guided by ctDNA dynamics demonstrate improved PFS2 compared to control patients assessed with conventional imaging alone.
- To evaluate overall survival (OS) in patients with metastatic TNBC who undergo treatment changes guided by ctDNA dynamics compared to control patients assessed by conventional imaging alone.
EXPLORATORY OBJECTIVES:
- To evaluate for unique predictive values of ctDNA-defined clones identified through the blood-based analysis.
- To correlate ctDNA changes with standard imaging.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive providers choice of standard of care chemotherapy and undergo blood sample collection for banking on study.
ARM B: Patients receive providers choice of standard of care chemotherapy and undergo blood sample collection for ctDNA evaluation on study. Patients may receive sacituzumab govitecan intravenously (IV) based on ctDNA results on study.
Patients in both arms A and B undergo computed tomography (CT) or magnetic resonance imaging (MRI) during screening and on study.
After completion of study treatment, patients are followed up at 3, 6, 9, and 12 months and then every 6 months for 3 years.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Vanderbilt-Ingram Services for Timely Access
- Phone Number: 800-811-8480
- Email: cip@vumc.org
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University/Ingram Cancer Center
-
Principal Investigator:
- Vandana Abramson, MD
-
Contact:
- Vanderbilt-Ingram Service for Timely Access
- Phone Number: 800-811-8480
- Email: cip@vumc.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Clinical stage IV (metastatic) estrogen receptor (ER), PR, HER2 negative invasive mammary carcinoma, previously documented by histological analysis and that meets the following criteria:
HER2 negativity is defined as any of the following by local laboratory assessment:
- In-situ hybridization (ISH) non-amplified (ratio of HER2 to CEP17 < 2.0 or
- Single probe average HER2 gene copy number < 4 signals/cell), or
- Immunohistochemistry (IHC) 0 or IHC 1+ (if more than one test result is available and not all results meet the inclusion criterion definition, all results should be discussed with the sponsor-investigator to establish eligibility of the patient)
- ER and PR negativity are defined as =< 10% of cells expressing hormonal receptors via IHC analysis
- PD-L1 negative (combined positive score [CPS] < 10) or otherwise not appropriate for checkpoint inhibitors
Patients must have measurable disease according to the standard RECIST version 1.1
* NOTE: CT scans or MRIs used to assess the measurable disease must have been completed with 28 days prior to the study drug initiation
- Patients must be age >= 18 years; both male and female are eligible
- Patients must exhibit an Eastern Cooperative Oncology Group (ECOG) performance status of =< 2
- Patients must have the ability to understand and the willingness to sign a written informed consent prior to registration on study
- No prior chemotherapy regimens for metastatic disease
- Absolute neutrophil count (ANC) >= 1000/mm^3 (obtained less than 28 days from initiation of study drug)
- Platelet count >= 100,000/mm^3 (obtained less than 28 days from initiation of study drug)
- Bilirubin, serum glutamic oxaloacetic transaminase (SGOT), serum glutatmic pyruvic transaminase (SGPT), alkaline phosphatase =< 4x upper limits of normal if no liver metastases present
- Serum total bilirubin must be < 3x upper limits of normal for patients with Gilbert disease
- Total bilirubin, SGOT, SGPT =< 6x upper limits of normal if liver metastases present (obtained less than 28 days from initiation of study drug)
For patients who are not postmenopausal (women) or surgically sterile (absence of ovaries and/or uterus or vasectomy), agreement to remain abstinent or to use two adequate methods of contraception (e.g., condoms, diaphragm, vasectomy/vasectomized partner, tubal ligation), during the treatment period and for at least 30 days after the last dose of study treatment. Hormone based oral contraceptives are not allowed on study. Postmenopausal is defined as:
- Age >= 55 years
- Age =< 55 years and amenorrheic for 12 months in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppression; or follicle stimulating hormone and estradiol in the postmenopausal range
Exclusion Criteria:
- Leptomeningeal disease
- Uncontrolled tumor-related pain: patients requiring narcotic pain medication must be on a stable regimen at registration. Symptomatic lesions (e.g., bone metastases or metastases causing nerve impingement) amenable to palliative radiotherapy should be treated prior to randomization. Patients should be recovered from the effects of radiation. There is no required minimum recovery period. Asymptomatic metastatic lesions whose further growth would likely cause functional deficits or intractable pain (e.g., epidural metastasis that is not presently associated with spinal cord compression) should be considered for loco-regional therapy if appropriate prior to randomization
- Uncontrolled hypercalcemia (> 1.5 mmol/L ionized calcium or calcium > 12 mg/dL or corrected serum calcium > upper limit of normal [ULN]) or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy
- Malignancies other than TNBC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer)
- Concurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biological therapy) other than the ones specified in the protocol
- Women only: pregnancy or lactation
- Evidence of significant uncontrolled concomitant disease that in the opinion of the investigator could affect compliance with the protocol or interpretation of results, including significant liver disease (such as cirrhosis, uncontrolled major seizure disorder, or superior vena cava syndrome)
- Significant cardiovascular disease, such as New York Heart Association (NYHA) cardiac disease (class II or greater), myocardial infarction within 3 months prior to randomization, unstable arrhythmias, or unstable angina. Patients with a known left ventricular ejection fraction (LVEF) < 35% will be excluded. Patients with known coronary artery disease or congestive heart failure not meeting the above criteria must be on a stable medical regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist if appropriate
- Major surgical procedure within 4 weeks prior to randomization or anticipation of the need for a major surgical procedure during the course of the study other than for diagnosis. Placement of central venous access catheter(s) (e.g., port or similar) is not considered a major surgical procedure and is therefore permitted
- Psychiatric illness/social situations that would compromise patient safety or limit compliance with study requirements
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm A (biospecimen banking)
Patients receive providers choice of standard of care chemotherapy and undergo blood sample collection for banking on study.
Patients undergo CT or MRI during screening and on study.
|
Undergo MRI
Undergo CT
Undergo blood sample collection for banking
Undergo blood sample collection for ctDNA evaluation
|
Experimental: Arm B (biospecimen evaluation, possible treatment change)
Patients receive providers choice of standard of care chemotherapy and undergo blood sample collection for ctDNA evaluation on study.
Patients may receive sacituzumab govitecan IV based on ctDNA results on study.
Patients undergo CT or MRI during screening and on study.
|
Undergo MRI
Undergo CT
Undergo blood sample collection for banking
Undergo blood sample collection for ctDNA evaluation
Given by IV
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (PFS)
Time Frame: Up to 3 years
|
The study survival will be estimated using the Kaplan-Meier method with 95% confidence intervals (CIs).
The CI based on the Greenwoods variance will be reported.
In addition, the efficacy of the study groups will be compared for PFS with log-rank tests.
For multivariate analysis, the proportional hazards Cox model will be applied to investigate potential prognostic factors, such as age, on the survival data.
The adjusted p-values of the hazard ratios and the adjusted 95% confidence intervals will be reported.
|
Up to 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events
Time Frame: From initiation of study-indicated treatment until 30 days after final study-indicated treatment or until initiation of another anticancer therapy, whichever occurs first
|
Adverse events will be graded according to the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events version 5.0.
Adverse medical events will be tabulated.
NCI toxicity grade 3 and grade 4 laboratory abnormalities will be listed.
|
From initiation of study-indicated treatment until 30 days after final study-indicated treatment or until initiation of another anticancer therapy, whichever occurs first
|
Progression free survival 2
Time Frame: Up to 3 years
|
The study survival will be estimated using the Kaplan-Meier method with 95% CIs.
The CI based on the Greenwoods variance will be reported.
In addition, the efficacy of the study groups will be compared for PFS2 with log-rank tests.
For multivariate analysis, the proportional hazards Cox model will be applied to investigate potential prognostic factors, such as age, on the survival data.
The adjusted p-values of the hazard ratios and the adjusted 95% confidence intervals will be reported.
|
Up to 3 years
|
Overall survival (OS)
Time Frame: Up to 3 years
|
The study survival will be estimated using the Kaplan-Meier method with 95% CIs.
The CI based on the Greenwoods variance will be reported.
In addition, the efficacy of the study groups will be compared for OS with log-rank tests.
For multivariate analysis, the proportional hazards Cox model will be applied to investigate potential prognostic factors, such as age, on the survival data.
The adjusted p-values of the hazard ratios and the adjusted 95% confidence intervals will be reported.
|
Up to 3 years
|
Response rate (RR)
Time Frame: Up to 3 years
|
The exact two-sided 95% confidence intervals for the RR will be reported for each arm.
The Fisher's exact test will be used to examine the difference of RR between treatment arms.
|
Up to 3 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Vandana Abramson, MD, Vanderbilt University/Ingram Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VICCBRE2257
- NCI-2023-01721 (Registry Identifier: NCI, Clinical Trials Reporting Program)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Triple-Negative Breast Carcinoma
-
Karolinska University HospitalRecruitingMetastatic Triple-Negative Breast CarcinomaSweden
-
Fundacio Clinic BarcelonaSOLTI Breast Cancer Research GroupNot yet recruitingMetastatic Triple-Negative Breast CarcinomaSpain
-
OncoPep, Inc.Not yet recruitingMetastatic Triple-Negative Breast Carcinoma
-
Memorial Sloan Kettering Cancer CenterRecruitingBreast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Breast Cancer Stage IV | Locally Advanced Breast Cancer | Metastatic Triple-Negative Breast Carcinoma | Locally Advanced Triple-Negative Breast CarcinomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingAnatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Unresectable Triple-Negative Breast CarcinomaUnited States
-
Roswell Park Cancer InstituteNot yet recruitingAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Unresectable Triple-Negative Breast Carcinoma | Refractory Triple-Negative Breast CarcinomaUnited States
-
National Cancer Institute (NCI)SuspendedAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Unresectable Triple-Negative Breast Carcinoma | Locally Advanced Triple-Negative Breast CarcinomaUnited States
-
National Cancer Institute (NCI)RecruitingAnatomic Stage IV Breast Cancer AJCC v8 | Invasive Breast Carcinoma | Metastatic Triple-Negative Breast CarcinomaUnited States
-
Yuan YuanGateway for Cancer Research; Agenus Inc.RecruitingAnatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast CarcinomaUnited States
-
OHSU Knight Cancer InstituteAstraZeneca; Oregon Health and Science UniversityRecruitingAnatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast CarcinomaUnited States
Clinical Trials on Magnetic Resonance Imaging
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingProstate Adenocarcinoma | Prostate CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Recruiting
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityRecruitingIntracranial NeoplasmUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Healthy SubjectUnited States
-
Stanford UniversityTerminatedLaryngeal Neoplasms | Head and Neck Cancers | Larynx CancerUnited States
-
University of California, San FranciscoTerminatedAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)CompletedBreast CancerUnited States
-
Abramson Cancer Center of the University of PennsylvaniaCompletedBrain TumorUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedThoracic Spine NeoplasmUnited States